Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 22 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Transforming Growth Factor Beta 1- Pipeline Review, H2 2018, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Gastrointestinal, Immunology, Ophthalmology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Osteoarthritis, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bone Disorders, Breast Cancer, Cholangitis, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hyperalgesia, Hypertrophic Scars, Inflammation, Lung Adenocarcinoma, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Pulmonary Hypertension, Scar, Solid Tumor, Squamous Cell Carcinoma, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook